Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Trifluoperazine dihydrochloride (SKF5019) is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | In stock | $ 50.00 |
Description | Trifluoperazine dihydrochloride (SKF5019) is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic. |
Targets&IC50 | Dopamine D2 receptor:1.1 nM |
In vitro | Trifluoperazine binds to α1A- and α1B-adrenoceptor with Ki value of 27.6 nM and 19.2 nM, respectively, with α1B/α1A ratio of 0.7. [2] Trifluoperazine inhibits Mycobacterium tuberculosis (Mtb) with MICs of 7.6 μg/mL. [3] Trifluoperazine (< 14.78 mM) suppresses the activities of the mouse splenic NK cell cytotoxicity and the effector-target cell conjugation in a dose dependent manner. Trifluoperazine suppresses interferon-alpha or interleukin-2 induced augmentation of the cytolytic activity of NK cells. [4] Trifluoperazine inhibits the gene expression of voltage-dependent potassium channel Kv2.1 from human brain (hKv2.1). [5] |
In vivo | Trifluoperazine dose dependently decreases avoidance responses and increases response failures in rats where behavior is maintained under a discrete-trial avoidance. [6] |
Synonyms | Trifluoperazine 2HCl, SKF5019, Urinox |
Molecular Weight | 480.43 |
Formula | C21H26Cl2F3N3S |
CAS No. | 440-17-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 88 mg/mL (183.2 mM)
DMSO: 82 mg/mL (170.7 mM)
Ethanol: 89 mg/mL (185.3 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Trifluoperazine dihydrochloride 440-17-5 Autophagy GPCR/G Protein Membrane transporter/Ion channel Microbiology/Virology Neuroscience CaMK Dopamine Receptor Influenza Virus Adrenergic Receptor P-gp SKF 5019 Inhibitor anticancer Multidrug resistance protein 1 Trifluoperazine 2HCl MDR1 inhibit Beta Receptor Calmodulin-dependent protein kinases ABCB1 SKF-5019 schizophrenia SKF5019 Cluster of differentiation 243 Trifluoperazine Trifluoperazine Dihydrochloride P-glycoprotein CD243 Calmodulin-dependent kinases Urinox NUPR1 morphogenesis Pgp antipsychotic inhibitor